GalNAc-siRNA Conjugates Drug Market - Global Forecast 2026-2032

The GalNAc-siRNA conjugates drug market is evolving rapidly as the industry emphasizes clinical evidence, scalable manufacturing, and commercialization strategies. Senior decision-makers face increasingly complex choices as innovation shifts from early validation to execution, with success determined by resilience, differentiation, and integrated supply capabilities.

Market Snapshot: GalNAc-siRNA Conjugates Drug Market Growth

The GalNAc-siRNA conjugates drug market expanded from USD 1.10 billion in 2025 to USD 1.19 billion in 2026 and is projected to reach USD 1.82 billion by 2032, with a projected CAGR of 7.45%. The sector benefits from its transition toward liver-targeted therapeutics, addressing unmet needs in cardiometabolic, hepatic, and rare genetic conditions. This consistent expansion follows improvements in targeted delivery, dosing convenience, and broader clinical adoption facilitated by robust chemistry and manufacturing controls.

Scope & Segmentation

Therapeutic Focus: Chronic cardiometabolic diseases, liver disorders, and rare genetic indications are leading applications as subcutaneous delivery and durable gene silencing underpin value creation.
Molecular Design: Advances in triantennary N-acetylgalactosamine ligand chemistry, backbone and sugar modifications, and linker strategies differentiate product profiles for efficacy, tolerability, and dosing interval.
Care Delivery Settings: Hospitals, specialty centers, and academic institutes are primary endpoints for patient identification, initiation, and long-term monitoring, alongside increasing outpatient opportunities as administration pathways improve.
Distribution Models: Controlled and specialty pharmacy distribution models are increasingly important, particularly for therapies requiring adherence support, outcomes documentation, and coordinated reimbursement navigation.
Geographies Covered: Americas (notably the United States), Europe, Asia-Pacific, Middle East, and Africa are included, with strategic priority based on diagnostic infrastructure, payer landscape, and manufacturing ecosystems.
Value Chain Players: Pharmaceutical innovators, biotech companies, contract development and manufacturing organizations (CDMOs), and specialty suppliers are central to execution and supply reliability.

Key Takeaways for Decision-Makers

Market competition now prioritizes integrated execution—clinical differentiation, chemistry innovation, manufacturability, and supply-chain resilience are critical to advancement.
Expansion into chronic and prevalent indications brings regulatory, payer, and trial design challenges that heighten the need for robust clinical and economic value demonstration.
Earlier attention to quality, impurity control, and manufacturing scalability reduces later-stage risk, helping align operational and regulatory milestones.
Distribution and patient support strategies increasingly determine successful launch and adoption, especially as dosing becomes less frequent and administration less complex.
Specialized CDMO partnerships and well-developed raw material supply chains provide companies a competitive edge in maintaining reliable operations.
Portfolio leaders balance established hepatic indications with targeted investments in next-generation chemistries to optimize outcomes and sustain growth.

Tariff Impact: Resilient Supply as a Strategic Differentiator

Upcoming United States tariffs are anticipated to affect sourcing costs and supply chain decisions for GalNAc-siRNA developers. As core manufacturing inputs and consumables are subject to cost volatility and qualification requirements, companies are prioritizing redundancy, dual sourcing, and regional supply agreements. Shifts in tariff policy push organizations to align procurement strategies with regulatory comparability and operational reliability, particularly for late-stage or high-volume programs.

GalNAc-siRNA Conjugates Drug Market: Methodology & Data Sources

This analysis applies a triangulated research model, combining scientific literature reviews, patent and regulatory analysis, clinical trial databases, and expert interviews. Insights are verified across stakeholders—including R&D leaders, clinicians, supply chain specialists, and market access executives—to ensure accuracy and consistency regarding technology progress, adoption barriers, and decision criteria.

Why This Report Matters

Get strategic clarity on how to optimize portfolio management, CMC strategy, and launch sequencing in a rapidly changing market environment.
Identify best practices for supply resilience, regulatory alignment, and payer-backed evidence to support confident investment and commercialization decisions.
Leverage up-to-date segmentation and regional analysis to align organizational resources with high-growth opportunities and mitigate operational bottlenecks.

Conclusion

GalNAc-siRNA conjugates have proven their potential across targeted liver indications. Sustained growth and competitive advantage now depend on end-to-end operational discipline, resilient partnerships, and execution that connects clinical innovation to value realization for patients and payers.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. GalNAc-siRNA Conjugates Drug Market, by Indication

8.1. Metabolic Disorders
8.1.1. Hypercholesterolemia
8.1.2. Type 2 Diabetes
8.2. Oncology
8.3. Rare Diseases
8.3.1. Hattr Amyloidosis
8.3.2. Hemophilia A

9. GalNAc-siRNA Conjugates Drug Market, by Patient Age Group

9.1. Adults
9.2. Pediatric

10. GalNAc-siRNA Conjugates Drug Market, by Application Type

10.1. Prophylaxis
10.2. Treatment

11. GalNAc-siRNA Conjugates Drug Market, by End User

11.1. Home Healthcare
11.2. Hospitals
11.3. Research Institutes
11.4. Specialty Clinics

12. GalNAc-siRNA Conjugates Drug Market, by Distribution Channel

12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies

13. GalNAc-siRNA Conjugates Drug Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. GalNAc-siRNA Conjugates Drug Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. GalNAc-siRNA Conjugates Drug Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States GalNAc-siRNA Conjugates Drug Market
17. China GalNAc-siRNA Conjugates Drug Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Akcea Therapeutics, Inc.
18.6. Alnylam Pharmaceuticals, Inc.
18.7. Arrowhead Pharmaceuticals, Inc.
18.8. AstraZeneca plc
18.9. BioNTech SE
18.10. CureVac N.V.
18.11. Dicerna Pharmaceuticals, Inc.
18.12. GlaxoSmithKline plc
18.13. Ionis Pharmaceuticals, Inc.
18.14. Moderna, Inc.
18.15. Novartis AG
18.16. Novo Nordisk A/S
18.17. Pfizer Inc.
18.18. Roche Holding AG
18.19. Sanofi S.A.
18.20. Sarepta Therapeutics, Inc.
18.21. Takeda Pharmaceutical Company Limited

List of Figures

FIGURE 1. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 99. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 100. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 101. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 102. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 114. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 115. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 116. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 117. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 118. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 131. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 132. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 133. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 134. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 135. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 139. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 140. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 141. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 142. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 143. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 156. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 157. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 158. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 159. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 163. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 164. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 165. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 166. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 167. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 171. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 172. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 173. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 174. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 175. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 180. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 184. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 187. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 188. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 189. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
TABLE 190. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 191. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
TABLE 192. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this GalNAc-siRNA Conjugates Drug market report include:

Akcea Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
AstraZeneca plc
BioNTech SE
CureVac N.V.
Dicerna Pharmaceuticals, Inc.
GlaxoSmithKline plc
Ionis Pharmaceuticals, Inc.
Moderna, Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
Sarepta Therapeutics, Inc.
Takeda Pharmaceutical Company Limited

Table Information

Report Attribute	Details
No. of Pages	192
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 1.19 Billion
Forecasted Market Value ( USD ) by 2032	$ 1.82 Billion
Compound Annual Growth Rate	7.4%
Regions Covered	Global
No. of Companies Mentioned	18

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,047GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,286GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,454GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,390GBP

Market Snapshot: GalNAc-siRNA Conjugates Drug Market Growth

Scope & Segmentation

Key Takeaways for Decision-Makers

Tariff Impact: Resilient Supply as a Strategic Differentiator

GalNAc-siRNA Conjugates Drug Market: Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

GalNAc-based Drug Market - Global Forecast 2026-2032

RNA Therapy Market - Global Forecast 2026-2032

Nucleic Acid Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

Oligonucleotide Therapy Market Report 2025

Amvuttra Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts